Kainos Medicine, Inc.

More mid-stage clinical trial failures are piling up in the Parkinson’s disease space, with the latest disappointment coming from South Korea's Bukwang Pharmaceutical Co., Ltd. , underlining the diff

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Daewoong, Vitalli Ink $447m Autoimmune

Kainos Medicine, Inc. has begun a two-stage US Phase II study of an in-house developed novel Parkinson’s disease (PD) drug candidate KM-819, which the Korean biotech aims to develop as a disease modi

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Emmaus, Kainos Tie Up To Develop IRAK4